Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Photocure increases currency-adjusted product revenue by 18% in Q1 2026
Photocure reports currency-adjusted product revenue growth of 18% for Q1 2026 and total revenue of NOK 264.6 million, significantly beating analyst estimates. Drivers were accelerated adoption of blue-light cystoscopy (BLC) in North America (26%) and Europe (11%) as well as milestone payments from partner Asieris. Adjusted EBITDA improved to NOK 15.3 million (Marche 11%), but reported EPS was -0.01 and missed expectations. Photocure confirms its 2026 guidance with expected currency-adjusted product revenue growth of 7–11% and further expansion of its market position for BLC. » Mere på de.investing.com
Photocure exceeds sales expectations in Q2 2025 and shares rise sharply
Photocure surpassed forecasts in the second quarter of 2025 with revenue of NOK 135.6 million, achieving 11% growth. The company reported positive EBITDA and a 12.01% increase in its share price, driven by strong results in North America and Europe as well as innovative product developments. Management confirmed its growth outlook and emphasized a strategic focus on expansion and partnerships. » Mere på de.investing.com
Photocure achieves record revenue in the second quarter of 2025 and focuses on strategic expansion
Photocure reported record revenue of NOK 135.6 million in the second quarter of 2025, representing 11% growth year-on-year. The company benefited from strong performance in North America and Europe, improved operational efficiency, and strategic partnerships and expansions, particularly in the US, Europe, and China. Photocure confirmed its 2025 outlook and believes it is well positioned for further growth through investments and innovation. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2013 har PhotoCure allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i juni 2013.
Virksomhedstal
I det seneste kvartal havde PhotoCure en omsætning på 12,93 mio. € og et nettoresultat på -2,4 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 12,93 mio. | 12,30 % |
| Bruttofortjeneste | 11,34 mio. | 14,89 % |
| Nettoresultat | -2,4 mio. | 807,67 % |
| EBITDA | 3,95 mio. | 220,87 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 102,85 mio. € |
Antal aktier | 26,97 mio. |
Højeste/laveste i 52 uger | 7,43 € - 3,81 € |
| Udbytte | Nej |
Beta | 0,35 |
P/E (PE Ratio) | 22,37 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 1,91 |
P/S (PS Ratio) | 1,62 |
Virksomhedsprofil
Photocure ASA, et specialiseret farmaceutisk selskab, beskæftiger sig med forskning, udvikling, produktion, distribution, markedsføring og salg af farmaceutiske produkter i de nordiske lande, Tyskland, Frankrig, Østrig, Storbritannien, Holland, Italien, andre europæiske lande og USA. Selskabet tilbyder Hexvix/Cysview til påvisning og behandling af blærekræft. Det udvikler desuden Cevira til behandling af humant papillomavirusinfektion og præcancerøse læsioner på livmoderhalsen. Selskabet sælger sine produkter til farmaceutiske grossister, apoteker og hospitaler via licenspartnere. Photocure ASA blev grundlagt i 1993 og har hovedkontor i Oslo, Norge.
| Navn | PhotoCure |
| CEO | Daniel Schneider |
| Hjemsted | Oslo,
ps Norge |
| Websted | |
| Børsnotering | 30.05.2000 |
| Medarbejdere | 101 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
Osl | PHO.OL |
London Stock Exchange | 0IMT.L |
Pnk | PHCUF |
Frankfurt | PHS.F |
Düsseldorf | PHS.DU |
London | 0IMT.L |